.
.
.
.

AstraZeneca exceeds sales and profits forecast amid coronavirus, outlook unchanged

Published: Updated:

Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.

For more on coronavirus, visit our dedicated section.

Product sales, which exclude payments from tie-ups, rose 9 percent to $6.05 billion in the three months ended June 30 on a constant-currency basis, surpassing analysts’ consensus of $6.01 billion.

Core earnings stood at 96 cents per share versus analysts’ estimate of 93 cents. Total revenue rose 11 percent, AstraZeneca said.

Read more:

Coronavirus: Abu Dhabi COVID-19 testing centers open during Eid al-Adha

Australia’s coronavirus outbreak continues to surge at alarming rate

Saudi Arabia: Hajj pilgrims in good health, no coronavirus cases among them so far